Performance Audit Report on the Procurement and Distribution of Drugs by Central Medical Stores (CMS)
Author: Botswana. Office of the Auditor General
Publisher:
Published: 2006
Total Pages: 104
ISBN-13:
DOWNLOAD EBOOKRead and Download eBook Full
Author: Botswana. Office of the Auditor General
Publisher:
Published: 2006
Total Pages: 104
ISBN-13:
DOWNLOAD EBOOKAuthor:
Publisher:
Published: 2017-11-27
Total Pages: 546
ISBN-13: 9781683086857
DOWNLOAD EBOOKIn addition to reprinting the PDF of the CMS CoPs and Interpretive Guidelines, we include key Survey and Certification memos that CMS has issued to announced changes to the emergency preparedness final rule, fire and smoke door annual testing requirements, survey team composition and investigation of complaints, infection control screenings, and legionella risk reduction.
Author: World Health Organization
Publisher:
Published: 2010
Total Pages: 84
ISBN-13:
DOWNLOAD EBOOKAuthor: Management Sciences for Health (Firm)
Publisher:
Published: 1997
Total Pages: 838
ISBN-13:
DOWNLOAD EBOOKThis edition of Managing Drug Supply provides a complete overview, as well as step-by-step approaches, on how to manage pharmaceutical systems effectively.
Author: Andreas Seiter
Publisher: World Bank Publications
Published: 2010-06-17
Total Pages: 240
ISBN-13: 0821383876
DOWNLOAD EBOOKThis book offers policy makers a hands-on approach, tested in the World Bank’s field work in many countries, for developing policies that improve access to safe, effective medicines in health systems of low- and middle-income economies.
Author: World Bank
Publisher:
Published: 2000
Total Pages: 238
ISBN-13:
DOWNLOAD EBOOKAuthor: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
Published: 2018-03-01
Total Pages: 235
ISBN-13: 0309468086
DOWNLOAD EBOOKThanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Aspen Health Law Center
Publisher:
Published: 1998
Total Pages: 156
ISBN-13:
DOWNLOAD EBOOKStepped-up efforts to ferret out health care fraud have put every provider on the alert. The HHS, DOJ, state Medicaid Fraud Control Units, even the FBI is on the case -- and providers are in the hot seat! in this timely volume, you'll learn about the types of provider activities that fall under federal fraud and abuse prohibitions as defined in the Medicaid statute and Stark legislation. And you'll discover what goes into an effective corporate compliance program. With a growing number of restrictions, it's critical to know how you can and cannot conduct business and structure your relationships -- and what the consequences will be if you don't comply.
Author: Alexander S. Preker
Publisher: World Bank Publications
Published: 2003
Total Pages: 646
ISBN-13: 9780821344941
DOWNLOAD EBOOKAs the largest expenditure category of the health systems in both industrialised and developing countries, hospital care provision has been the focus of reforms over recent decades. This publication reviews recent trends in hospital policy reforms and options around the world; and includes case studies which offer insights into lessons learned. Issues considered include: differences in income levels, cultural settings and market environments; organisational changes such as increased management autonomy and privatisation; the need for parallel reforms and effective evaluation mechanisms.
Author: Institute of Medicine
Publisher: National Academies Press
Published: 2013-06-20
Total Pages: 377
ISBN-13: 0309269393
DOWNLOAD EBOOKThe adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.